CytoGenix, Inc. has received a notice of allowance for a patent on its original single stranded DNA expression plasmid vectors in Australia.
The patent, entitled “Production of ssDNA in vivo,” claims both compositions and methods for using the single stranded DNA expression vectors.
The subject matter includes several variations of the expression vector system for inducing cells to produce specifically designed single strands of DNA which may be used in antisense, aptamer, triplex or DNA enzyme applications. The claimed system provides a more advanced and flexible approach for using the Company’s proprietary ssDNA expression system.
“The award of this allowance provides further validation of CytoGenix technology and improves the Company’s ability to secure strategic partners that can assist in commercialization of CytoGenix products using this ssDNA expression system,” stated Malcolm Skolnick, CytoGenix President and Chief Executive Officer.
Dr. Yin Chen, Chief Scientific Officer and co-inventor of the technology, comments, "This is a significant step forward for CytoGenix because the technology has broad application in potential therapeutics and high-throughput drug screening.”